XML 29 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information
 3 Months Ended
Mar. 31, 2019
Segment Information  
Segment Information

11.   Segment Information

We currently operate as one operating segment with a focus on the development and commercialization of products to address the unmet needs of patients with chronic and life-threatening conditions. Our Chief Executive Officer, as our chief operating decision maker, manages and allocates resources to the operations of our company on a consolidated basis. This enables our Chief Executive Officer to assess our overall level of available resources and determine how best to deploy these resources across functions, therapeutic areas, and research and development projects in line with our long-term company-wide strategic goals.

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31, 

2019

    

Remodulin

    

Tyvaso

    

Orenitram

    

Unituxin

    

Adcirca

    

Total

Net product sales

 

$

155.5

 

$

103.8

 

$

58.4

 

$

24.9

 

$

20.0

 

$

362.6

Cost of product sales

 

 

6.1

 

 

4.4

 

 

4.8

 

 

5.1

 

 

8.7

 

 

29.1

Gross profit

 

$

149.4

 

$

99.4

 

$

53.6

 

$

19.8

 

$

11.3

 

$

333.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net product sales

 

$

126.8

 

$

94.6

 

$

52.2

 

$

18.0

 

$

97.6

 

$

389.2

Cost of product sales

 

 

3.0

 

 

3.0

 

 

3.0

 

 

2.3

 

 

41.9

 

 

53.2

Gross profit

 

$

123.8

 

$

91.6

 

$

49.2

 

$

15.7

 

$

55.7

 

$

336.0

 

Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in millions):

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31, 

 

    

2019

    

2018

United States

 

$

329.5

 

$

365.8

Rest-of-World(1)

 

 

33.1

 

 

23.4

Total

 

$

362.6

 

$

389.2

(1)Primarily Europe.

We recorded revenue from two specialty pharmaceutical distributors in the United States comprising 58 percent and 20 percent, respectively, of total revenues during the three-month period ended March 31, 2019 and 48 percent and 16 percent, respectively, of total revenues during the three-month period ended March 31, 2018. All of our revenues for Adcirca are generated by sales made through Lilly’s pharmaceutical wholesaler network.